Evidence map›Paper›PMID 30046297›Full record

ArticleFrontiers in immunology2018

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, Arlene Naranjo, Mitchell B Diccianni, Sheena C Tenney, Malcolm Smith, Karen S Messer, Robert Seeger, C Patrick Reynolds and 7 more

Abstract readPublished Erratum
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

M Fevzi OzkaynakNew York Medical College, Valhalla, NY, United States.
Andrew L GilmanLevine Children's Hospital, Charlotte, NC, United States.
Wendy B LondonDana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.
Arlene NaranjoChildren's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, United States.
Mitchell B DiccianniMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Sheena C TenneyChildren's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, United States.
Malcolm SmithNational Cancer Institute, Bethesda, MD, United States.
Karen S MesserMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.
Robert SeegerChildren's Hospital Los Angeles, University Southern California, Los Angeles, Los Angeles, CA, United States.
C Patrick ReynoldsTexas Tech University Health Sciences Center, Lubbock, TX, United States.
L Mary SmithUnited Therapeutics, Silver Spring, MD, United States.
Barry L ShulkinSt. Jude's Children's Research Hospital, Memphis, TN, United States.
Marguerite ParisiSeattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, United States.
John M MarisChildren's Hospital of Philadelphia, Philadelphia, PA, United States.
Julie R ParkSeattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, United States.
Paul M SondelUniversity of Wisconsin Carbone Cancer Center, Madison, WI, United States.
Alice L YuMoores Cancer Center, University of California, San Diego, La Jolla, CA, United States.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Enhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4M
NCI NIH HHS R35 CA197078NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899
6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fimmu.2018.01355.].

Indexed as

anti-GD2 chimeric antibodycytokine biomarkerscytokinesimmunotherapyneuroblastomasafety

Identifiers

PMID30046297
PMCPMC6055015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.